CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical CML papers

Asciminib remained superior versus bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Mauro MJ et al. Blood Adv, May 2025 (epub ahead of print)
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patient failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trials
le Coutre P et al. Acta Haematol, May 2025 (epub ahead of print)
Pharmacokinetic profile of novel reduced-dose Danziten TM (Nilotinib tablets) versus Tasigna TM (Nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis
Mauro MJ et al. Cancer Chemother Pharmacol, May 2025 – open access publication
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC
Johnson-Ansah H et al. Leuk Res, May 2025 (epub ahead of print)
Real-world efficacy profile of compassionate use of asciminib in an Italian, multi-resistant chronic-phase chronic myeloid leukemia (CP-CML) patient population
Breccia M et al. Hematol Oncol, May 2025 – open access publication
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Zhang X et al. Haematologica, April 2025 (epub ahead of print) – open access publication
Bosutinib for successful treatment-free remission in chronic myeloid leukemia
Fujioka Y et al. Cancer Med, May 2025 – open access publication
Optimal depth of the treatment response before allogeneic hematopoietic transplantation for chronic myeloid leukemia in chronic phase
Okada Y et al. Am J Hematol, May 2025 (epub ahead of print) – open access publication
Incidence of cardiovascular events and carotid artery USG abnormalities in chronic myeloid leukemia patients on nilotinib therapy: A 20-year single center study
Jang Y et al. Clin Lymphoma Myeloma Leuk, April 2025 (epub ahead of print)
Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia: A review
Jajosky AN and Lichtman MA. Haematologica, May 2025 (epub ahead of print) – open access publication
Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction
Andersson P et al. Clin Pharm, December 2024 – open access publication

Scientific CML papers

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers - Review
Sicuranza A et al. Front Oncol, May 2025 – open access publication
BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
Mancini C et al. Cancer Cell Int, May 2025 – open access publication
GPX1 confers resistance to metabolic stress in BRC/ABL-T315I mutant chronic myeloid leukemia cells
Wang JD et al. Cell Death Disc, May 2025 – open access publication

More CML Publications 2025

Clinical Publications	Scientific Publications
May 2025
Chronic myeloid leukemia: A review Jabbour E and Kantarjian H. JAMA, May 2025	Research of the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia Feng X et al. Discov Oncol, May 2025 – open access publication
Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis - Review Smit Y et al. Support Care Cancer, May 2025 – open access publication	BCR-ABL: The molecular mastermind behind chronic myeloid leukemia – Review Shammas T et al. Cytokine Growth Factor Rev, May 2025 (epub ahead of print) – open access publication
Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in CML: Insights from a multicenter retrospective study in real-world practice Hibino Y et al. Leuk Res, May 2025	Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia - Review Irgit A et al. Arch Pharm (Weinheim), May 2025 – open access publication
Management of chronic-phase chronic myeloid leukemia in later lines: A Hong Kong consensus recommendation Cheung CYM et al. Ann Hematol, May 2025 (epub ahead of print)
Real world evidence from 2 decades of first-line TKI therapy in chronic myeloid leukemia (CML): Insights from ACHO’s RENEHOC Registry Abello Polo V et al. Clin Lymphoma Myeloma Leuk, May 2025 – open access publication
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617F mutation by combination therapy with asciminib and ropeginterferon alpha-2b in an elderly patient Oka S et al. Int J Hematol, May 2025 (epub ahead of print)
April 2025
Chronic myeloid leukemia Treatment (PDQ): Patient Version PDQ Adult Treatment Editorial Board, April 2025 – open access publication	KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT(+) blast phase chronic myeloid leukemia Kwon HJ et al. Mol Cancer, April 2025 – open access publication
Molecular response with Ascminib 20 mg QD in a patient intolerant to multiple TKIs Stuckey R et al. Ann Hematol, April 2025 (epub ahead of print) – open access publication	High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia Nygrén P et al. Blood, April 2025 – open access publication
Asciminib monotherapy in patients with chronic myeloid leukemia chronic-phase without BCR::ABL1 T315I treated with at least 2 prior tyrosine kinase inhibitors: Phase 1 final results Hochhaus A et al. Leukemia, April 2025 (epub ahead of print) – open access publication	A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia Bica V et al. Cell Commun Signal, April 2025 – open access publication
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results Cortes JE et al. Leukemia, April 2025 (epub ahead of print) – open access publication	The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis Thuy VT et al. Leuk Res, April 2025
Olverembatinib in chronic myeloid leukemia – Review of historical development, current status, and future research Kantarjian H et al. Cancer, April 2025	Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia Xie Y et al. Cell Death Dis, April 2025 – open access publication
Successful treatment-free remission after ponatinib discontinuation in pretreated patients with chronic myeloid leukemia in chronic-phase Haddad FG et al. Clin Lymphoma Myeloma Leuk, April 2025	SMAC mimetics in action in chronic myeloid leukemia Turhan AG. Blood, April 20
CAR-T cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: A multicenter clinical analysis Liu Y et al. Cancer Lett, April 2025 (epub ahead of print)	SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability Mancini M et al. Clin Transl Med, April 2025 – open access publication
Prognostic scoring system in chronic myeloid leukemia – Review Lauseker M et al. Leukemia, April 2025 (epub ahead of print) – open access publication	Timing and trajectory of BCR::ABL1-driven chronic myeloid leukemia Kamizela AE et al. Nature, April 2025 – open access publication
How I individualize treatment for chronic-phase CML Leyte-Vidal AM and Shah NP. Blood, April 2025 (epub ahead of print)
Synergistic effect of asciminib with reduced doses of ponatinib in human Ph+ myeloid leukemia with the T315M mutation Nguyen T et al. Int J Hematol, April 2025 (epub ahead of print) – open access publication
Tyrosine kinase inhibitor treatment patterns in patients with chronic-phase chronic myeloid leukemia: A single centre data from China Yuan MY et al. Clin Lymphoma Myeloma Leuk, April 2025
March 2025
Twin pregnancy during treatment with asciminib for chronic myeloid leukemia – a care report Gutierrez de Moraes Pereira GBBM. Ann Hematol, March 2025 (epub ahead of print) – open access publication	PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3 Barik B et al. Cell Death Dis, March 2025 – open access publication
Nilotinib induced diabetes in Japanese patients with chronic myeloid leukemia Iwamoto Y et al. Intern Med, March 2025 – open access publication	Different in vitro models of chronic myeloid leukemia show different characteristics: Biological replicates are not biologically equivalent Cavalleri A et al. Cell Biol Int, March 2025 (epub ahead of print) – open access publication
Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B photography Beeler JS et al. Haematologica, March 2025 – open access publication	Comprehensive analysis of tyrosine kinase inhibitor domain mutations and imatinib resistance in chronic myeloid leukemia patients Dhangar S et al. Leuk Res, March 2025 (epub ahead of print)
Alternative routes of drug administration: Exposure of imatinib using different formulations Fiebrich-Westra HB et al. Cancer Chemother Pharmacol, March 2025	Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukemia Sun C et al. Nat Cell Biol, March 2025 (epub ahead of print)
Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission Camado MF et al. Clin Exp Med, March 2025 – open access publication	Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print)
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway Wang J et al. Nat Cancer, March 2025 (epub ahead of print)	Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter? Dalgetty M and Cortes JE. Blood, March 2025 (epub ahead of print)
	Imatinib and the dawn of precision cancer medicine Druker BJ. Nat Med, March 2025
	Living, not just surviving with CML – quality of life to the front of the line Lipton JH and Rea D. Leukemia, March 2025 (epub ahead of print)
	Chronic myeloid leukemia: A review Jabbour E and Kantarjian H. JAMA, March 2025 (epub ahead of print)
	Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors Rodrigues Moreira P et al. J Oncol Pharm Pract, March 2025 (epub ahead of print)
	Do we need another TKI for chronic myeloid leukemia? Hjorth-Hansen H. Lancet Haematol, March 2025
	Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study Busque L et al. Blood Cancer J, March 2025 – open access publication
February 2025
Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving Olverembatinib: Quality of life matters! Eşkazan AE. Cancer, February 2025	Autophagy and Cancer: Insights into molecular mechanisms and therapeutic approaches for chronic myeloid leukemia – Review Kausar MA et al. Biomolecules, February 2025 – open access publication
Novel treatment strategies for chronic myeloid leukemia – Review Cruz-Rodriguez N and Deininger MW. Blood, February 2025	CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells Guoyun J et al. Exp Hematol, February 2025 – open access publication
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia – Review Guilhot F and Hehlmann R. Blood, February 2025	MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Box, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells Kimura A et al. Biomed Rep, February 2025 – open access publication
Unrelated bone marrow transplantation for CML after liver transplantation Watanabe M et al. Intern Med, February 2025 (epub ahead of print) – open access publication	MiR-142 deficit in T-cells during blast crisis promotes chronic myeloid leukemia immune escape Chen F et al. Nat Commun, February 2025 – open access publication
Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1/A337V can be effectively overcome with dasatinib treatment Batar P et al. Curr Oncol, February 2025 – open access publication	Low-dose bee venom as a potential target against human chronic myeloid leukemia cells Halici H et al. Protein J, February 2025 (epub ahead of print)
A CML patient carrying BCR::ABL1 splicing variant did not experience blast crisis for 15 years without responding to various TKIs Nakamura F et al. Intern Med, February 2025 – open access publication	Circumventing imatinib resistance in chronic myeloid leukemia: Novel Telmirsatan-based cell death modulators with improved activity and stability Gebhart M et al. Eur J Med Chem, February 2025 – open access publication
Ophthalmic findings leading to diagnose chronic myeloid leukemia: A multimodal image case report Hoyos A et al. Eur J Ophthalmol, February 2025 (epub ahead of print)	Proliferation inhibited by Genipin in human leukemia K562 cells: Involvement of uncoupling protein 2 in mitochondrial damage Zhou Y et al. World J Oncol, February 2025 (epub ahead of print) – open access publication
Asciminib in the treatment of chronic myeloid leukemia chronic phase – Review Costa A et al. Future Oncol, February 2025 (epub ahead of print)	CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR Signaling Pathway Miyashita N et al. Cancer Sci, February 2025 (epub ahead of print) – open access publication
A nomogram for predicting T315I-free survival in chronic-phase chronic myeloid leukemia patients: A multicentre retrospective study Hu SW et al. Sci Rep, February 2025 – open access publication
Introduction to a series of reflections on a quarter century of TKIs for CML Druker BJ. Blood, February 2025 – open access publication
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1 / 2 trial Cortes JE et al. Lancet Haematol, February 2025 (epub ahead of print)
Blast-phase chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia Shuyu E et al. Am J Clin Pathol, February 2025
Inflammatory/immune adverse events in chronic myeloid leukemia patients during treatment with Bosutinib Agostani E et al. Cancer Med, February 2025 – open access publication
Total psoriasis regression in a patient with chronic myeloid leukemia treated using Nilotinib Horňák T et al. Ann Hematol, February 2025 (epub ahead of print) – open access publication
Fibrosis and treatment-free remission in chronic myeloid leukemia Brailovski E et al. Br J Haematol, February 2025 (epub ahead of print)
BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration-approved droplet-based PCR assay Kockerols C et al. J Mol Diagn, February 2025 – open access publication
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia Abumiya M et al. Int J Hematol, February 2025 (epub ahead of print) – open access publication
Treatment-free remission outcomes in BCR::ABL1 digital PCR selected clinical cohort of chronic myeloid leukemia patients Kockerols C et al. Eur J Haematol, February 2025 (epub ahead of print) – open access publication
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukemia Gong X et al. Leukemia, February 2025 (epub ahead of print) – open access publication
Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia Chen EY et al. Eur J Haematol, February 2025 – open access publication
January 2025
Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial Jabbour E et al. JAMA Oncol, January 2025	Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line Jaafari N et al. PLoS, January 2025 – open access publication
Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life Cho HJ et al. Acta Haematol, January 2025 (epub ahead of print)	Exploring the significance of MDM2 gene promotes variants in chronic myeloid leukemia Fontecha MB et al. Leuk Res, January 2025 (epub ahead of print)
Bosutinib for the treatment of CML – using it safely: a Podcast Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print) – open access publication	N-Degron PROTACs as a potential therapeutic approach for chronic myeloid leukemia Hohmann G & Eldeeb MA. Anticancer Agents Med Chem, January 2025 (epub ahead of print)
The evolution of treatment-free remission Hughes TP et al. Blood, January 2025 (epub ahead of print)	Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL positive leukemia Luo Z et al. Cancer Res, January 2025 – open access publication
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia Qian Z et al. Bioorg Chem, January 2025 (epub ahead of print)	Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells Sun X et al. Biochem Pharmacol, January 2025 (epub ahead of print)
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different? Maduado C et al. ESC Heart Fail, January 2025 (epub ahead of print) – open access publication	Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia Minhajuddin M et al. Haematologica, January 2025 – open access publication
Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025	LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting Quijada-Alamo M et al. Haematologica, January 2025 – open access publication
Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia Li Z et al. Cancer, January 2025 – open access publication	Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia Komic H et al. Haematologica, January 2025 – open access publication
Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib Yu L et al. Cancer, January 2025 – open access publication	High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia Nygren PJ et al. Blood, January 2025 (epub ahead of print)
Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid) Sasaki K. Cancer, January 2025	Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells Rocco S et al. J Clin Med, January 2025 – open access publication
Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors Kondo T et al. Cancer, January 2025 – open access publication	EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia Brunmeier R et al. Leukemia, January 2025 (epub ahead of print) – open access publication
Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group Giordano U et al. Biomedicines, January 2025 - open access publication
Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia Mayer J et al. Am J Hematol, January 2025 (epub ahead of print) – open access publication
Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases Yousefi A et al. Ann Hematol, January 2025 (epub ahead of print) – open access publication
Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study Szuber N et al. Future Oncol, January 2025 (epub ahead of print) – open access publication
Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice Aleem A et al. Clin Lymphoma Myeloma Leuk, January 2025
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy Shen Q et al. Leuk Lymphoma, January 2025 (epub ahead of print)